Dealing with double trouble: Combination deworming against double-drug resistant cyathostomins. (April 2020)

• Record Type: Journal Article
• Authors: Scare, J.A.; Leathwick, D.M.; Sauermann, C.W.; Lyons, E.T.; Steuer, A.E.; Jones, B.A.; Clark, M.; Nielsen, M.K.
• Is Part Of: International journal for parasitology. Volume 12(2020)
• Page Start: 28
• Page End: 34
• Publication Date: 2020-04
• Subjects: Moxidectin -- Combination -- Deworming -- Cyathostomin -- Oxibendazole -- Equine; Parasitic diseases -- Chemotherapy -- Periodicals; Drug resistance -- Periodicals; 616.96061
• DOI: 10.1016/j.ijpddr.2019.12.002
• Languages: English
• ISSNs: 2211-3207

Abstract

Abstract: An alternative control regimen for drug-resistant parasites is combination deworming, where two drugs with different modes of action are administered simultaneously to target the same parasite. Few studies have investigated this in equine cyathostomins. We previously reported that an oxibendazole (OBZ) and pyrantel pamoate (PYR) combination was not sustainable against a cyathostomin population with high levels of OBZ and PYR resistance. This study consisted of a field study and two computer simulations to evaluate the efficacy of a moxidectin-oxibendazole (MOX-OBZ) combination against the same cyathostomin population. In the field study, anthelmintic treatments occurred when ten horses exceeded 100 eggs per gram. Fecal egg counts and efficacy evaluations were performed every two weeks. The two simulations utilized weather data as well as equine and parasite population parameters from the field study. The first simulation repeated the treatment schedule used in the field study over a 40 year period. The second evaluated efficacies of combination treatments using selective therapy over 40 years. In the field study, efficacies of MOX and both combination treatments were 100%. The egg reappearance period for MOX was 16 weeks, and the two combination treatments were 12 and 18 weeks. The first (46.7%) and last (40.1%) OBZ efficacies were not significantly different from each other. In the simulation study, the combination treatment delayed MOX resistance development compared to when MOX was used as a single active. This occurred despite the low efficacy of OBZ. The second set of simulations identified combination treatments used with selective therapy to be the most effective at delaying MOX resistance. Overall, this study supports the use of combination treatment against drug-resistant cyathostomins, when one of the actives exhibits high efficacy, and demonstrates benefits of this approach despite substantially lowered efficacy of the other active ingredient. Graphical abstract: Image 1 Highlights: Oxibendazole-moxidectin combination treatments were 100% effective. Oxibendazole efficacies (<50%) did not differ pre and post combination treatment. The model observed oxibendazole-moxidectincombinationto delaymoxidectin resistance. Combination use in selective therapy delayed resistance most effectively.